Halozyme CEO sells 60,000 shares under 10b5-1 plan
HALOZYME THERAPEUTICS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
HALOZYME THERAPEUTICS, INC. (HALO) reported that President and CEO Helen Torley exercised stock options for 60,000 shares of common stock at an exercise price of $18.41 per share over September 9–11, 2026, and sold 60,000 shares at weighted average prices around $107 per share under a pre-arranged Rule 10b5-1 trading plan.
Insider Trade Summary 10b5-1
Exercise and Sale: 60,000 shares ($5.33M approx. pre-tax spread)
Exercise and Sale
13 txns
Insider
Torley Helen
Role
PRESIDENT AND CEO
Sold
60,000 shs ($6.44M)
Approx. gross sale proceeds
$6.44M
Approx. exercise cost
$1.10M
Approx. pre-tax spread
$5.33M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock F1, F8 | 20,000 | $18.41 | $368K |
| Exercise | Common Stock F1 | 20,000 | $18.41 | $368K |
| Sale | Common Stock F1, F6 | 15,492 | $107.154 | $1.66M |
| Sale | Common Stock F1, F7 | 4,508 | $107.548 | $485K |
| Exercise | Option to Purchase Common Stock F1, F8 | 20,000 | $18.41 | $368K |
| Exercise | Common Stock F1 | 20,000 | $18.41 | $368K |
| Sale | Common Stock F1, F4 | 14,588 | $107.012 | $1.56M |
| Sale | Common Stock F1, F5 | 5,412 | $107.581 | $582K |
| Exercise | Option to Purchase Common Stock F1, F8 | 20,000 | $18.41 | $368K |
| Exercise | Common Stock F1 | 20,000 | $18.41 | $368K |
| Sale | Common Stock F1, F2 | 13,304 | $107.222 | $1.43M |
| Sale | Common Stock F1, F3 | 6,596 | $107.821 | $711K |
| Sale | Common Stock F1 | 100 | $108.67 | $11K |
Holdings After Transaction:
Option to Purchase Common Stock — 81,552 contracts (Direct);
Common Stock — 767,780 shares (Direct)
Footnotes (8)
- F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
- F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.640 to $107.632. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.640 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.360 to $107.350 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- F5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.360 to $107.820 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- F6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.400 to $107.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.400 to $107.960. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F8. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.
Key Figures
Options exercised: 60,000 shares
Shares sold: 60,000 shares
Option exercise price: $18.41 per share
+5 more
8 metrics
Options exercised
60,000 shares
Total option shares exercised by the CEO over September 9–11, 2026
Shares sold
60,000 shares
Total Halozyme common shares sold over September 9–11, 2026
Option exercise price
$18.41 per share
Exercise price for options converted into 60,000 common shares
Sale price range
$106.36–$108.29 per share
Price ranges for weighted average sales prices noted in multiple tranches
Representative sale prices
$107.01–$107.82 per share
Examples of weighted average sale prices reported for individual sale rows
Rule 10b5-1 plan adoption date
December 3, 2025
Date the CEO’s written trading plan governing these trades was adopted
Option grant date
February 14, 2018
Grant date for the 10-year stock options that were exercised
Option expiration
February 2028
Stated expiration timing for the exercised 10-year term options
Key Terms
Rule 10b5-1, trading plan, weighted average sales price per share, stock options, +1 more
5 terms
Rule 10b5-1 regulatory
"made pursuant to a written trading plan adopted ... in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
trading plan financial
"The options exercised and sales ... were made pursuant to a written trading plan"
A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.
stock options financial
"shares that were acquired following exercise of stock options with a ten-year term"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
expiration date financial
"stock options with a ten-year term expiring in February 2028"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did HALO CEO Helen Torley report on this Form 4 for HALO?
Helen Torley reported exercising 60,000 stock options at $18.41 per share and selling 60,000 common shares over September 9–11, 2026, at weighted average prices around $107 per share, all under a Rule 10b5-1 trading plan.
What prices were involved in the HALO CEO’s option exercises and sales?
Options were exercised at an exercise price of $18.41 per share. The resulting common shares were sold at weighted average prices around $107 per share, with reported ranges from about $106.36 to $108.29 per share across the different sale tranches.
Were the HALO CEO’s Form 4 transactions made under a Rule 10b5-1 plan?
Yes. The filing states the option exercises and sales were made pursuant to a written Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2025, indicating the trades were pre-arranged under that plan.
What options did the HALO CEO exercise in this Form 4?
The CEO exercised stock options covering a total of 60,000 shares of common stock at $18.41 per share. Footnotes state these options were granted on February 14, 2018, had a 10-year term, and were scheduled to expire in February 2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.
